11 active not recruiting. 11 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 11 |
| Phase 1 | 4 | Active not recruiting 4 |
Follow Cardiovascular Abnormalities: new trials by email Literature Review of Cardiovascular Abnormalities trials Research Report on Cardiovascular Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trametinib Treatment for Complicated Vascular Anomalies Trametinib tablet - Vascular Anomalies | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 20 | 2025-07-07 | 2025-07-22 |
| A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment Vosoritide Injection - Noonan Syndrome | Phase 2 | Active not recruiting | BioMarin Pharmaceutical | 30 | 2024-11-22 | 2026-09-23 |
| A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) ALN-6400, Placebo - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 89 | 2024-11-07 | 2026-10-15 |
| Gene Therapy for ACM Due to a PKP2 Pathogenic Variant LX2020 - Arrhythmogenic Cardiomyopathy, PKP2-ACM | Phase 1 / Phase 2 | Active not recruiting | Lexeo Therapeutics | 10 | 2024-02-29 | 2025-11-12 |
| A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome Lonapegsomatropin, Somatropin - Turner Syndrome | Phase 2 | Active not recruiting | Ascendis Pharma Endocrinology Division A/S | 48 | 2023-02-15 | 2026-05-13 |
| Assess Safety and Efficacy of VAD044 in HHT Patients VAD044 Part I, VAD044 Part II - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 / Phase 2 | Active not recruiting | Vaderis Therapeutics AG | 75 | 2022-07-18 | 2026-03-17 |
| Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. Lomecel-B medicinal signaling cells - Hypoplastic Left Heart Syndrome | Phase 2 | Active not recruiting | Longeveron Inc. | 40 | 2021-06-25 | 2025-06-25 |
| Bevacizumab In Hereditary Hemorrhagic Telangiectasia Bevacizumab (Avastin®) - Hereditary Hemorrhagic Telangiectasia | Phase 2 | Active not recruiting | Hanny Al-Samkari, MD | 33 | 2020-11-23 | 2026-05-05 |
| Vosoritide for Selected Genetic Causes of Short Stature Vosoritide - Short Stature | Phase 2 | Active not recruiting | Andrew Dauber | 56 | 2020-08-04 | 2026-03-18 |
| Optical Tissue Identification for Myocardial Architecture Fluorescite, Cellvizio 100 Series System with Confocal Miniprobes - Ventricular Septal Defect, Complete Atrioventricular Canal | Phase 2 | Active not recruiting | Aditya Kaza | 70 | 2019-12-20 | 2023-06-15 |
| Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome Autologous (self) mononuclear cells derived from umbilical cord blood, Stage II Surgical repair - Hypoplastic Left Heart Syndrome | Phase 2 | Active not recruiting | Timothy J Nelson, MD, PhD | 95 | 2019-06-06 | 2025-07-08 |
Telangiectasia, Hereditary Hemorrhagic (3) · Dwarfism (2) · Hypoplastic Left Heart Syndrome (2) · Noonan Syndrome (2) · Arrhythmogenic Right Ventricular Dysplasia (1) · Arteriovenous Malformations (1) · Bone Diseases (1) · Cardiomyopathies (1) · Complete atrioventricular septal defect (1) · Death, Sudden, Cardiac (1) · Epistaxis (1) · Heart Arrest (1) · Heart Defects, Congenital (1) · Heart Septal Defects, Ventricular (1) · Hypochondroplasia (1)
Cardiovascular Diseases (11) · Congenital Abnormalities (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Heart Diseases (7) · Heart Defects, Congenital (6) · Endocrine System Diseases (3) · Genetic Diseases, Inborn (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Telangiectasis (3) · Vascular Diseases (3) · Vascular Malformations (3)
vosoritide (2) · Bevacizumab (1) · Fluorescein (1) · Human Growth Hormone (1) · lonapegsomatropin (1) · trametinib (1)
Aditya Kaza (1) · Alnylam Pharmaceuticals (1) · Andrew Dauber (1) · Ascendis Pharma Endocrinology Division A/S (1) · BioMarin Pharmaceutical (1) · Hanny Al-Samkari, MD (1) · Lexeo Therapeutics (1) · Longeveron Inc. (1) · Timothy J Nelson, MD, PhD (1) · Vaderis Therapeutics AG (1) · West China Hospital (1)
United States (10) · France (3) · Spain (3) · Australia (2) · Canada (2) · Germany (2) · Italy (2) · Belgium (1) · China (1) · Netherlands (1)
Aditya K Kaza, MD (1) · Andrew Dauber, MS MMSc (1) · Benjamin Peeler, M.D. (1) · Damien Picard (1) · David M. Overman, M.D. (1) · Frank Cetta, MD (1) · Hanny Al-Samkari, MD (1) · Harold M. Burkhart, M.D. (1) · James Jaggers, M.D. (1) · James Tweddell, M.D. (1) · Joseph W. Rossano, M.D. (1) · Ram Kumar Subramanyan, M.D., Ph.D. (1)
PMID 24252784, PMID 30542204, PMID 32894644, PMID 37264205, PMID 38813446, PMID 40102890, PMID 40312733, PMID 41297007
2025 (1), 7UG3HL148318-02 (1), R56HL128813 (1), U24HL148316 (1)